Plate Nº 84 · recorded November 17, 2026
Neuroscience & MindReported finding
Psilocybin Rewires Stressed Mouse Brains Without the Trip, Study Finds
UC Santa Cruz researchers found psilocybin reshapes neural connections in stressed mice through a pathway separate from the one behind psychedelic effects, pointing toward non-hallucinogenic drugs.
By Elena Vasquez5 min read993 words
In brief
- New dendritic spines increased substantially within 24 hours of psilocybin administration in mice.
- The study is published in the journal Nature Neuroscience by researchers at UC Santa Cruz.
- Restoring serotonin 2A receptors only in Layer 5 pyramidal neurons recovered brain rewiring without the head-twitch response.
- In chronically stressed mice, psilocybin boosted new spine formation and reduced loss of existing connections over three weeks of observation.
- All findings are from mice; no clinical or human data are included.
Psilocybin, the psychoactive compound in magic mushrooms, can reshape neural connections in the brain through a cellular mechanism that works separately from the one driving psychedelic effects. That's the central finding of a new mouse study published in the journal Nature Neuroscience, and it opens a possible path to psychedelic-inspired psychiatric drugs that don't require an intense altered state of consciousness.
The work comes from researchers at UC Santa Cruz. It's a major step, according to one of its authors.
"I consider this work a major advance, particularly in our understanding of how psilocybin reshapes neural circuits and its potential implications for treating mental disorders," said Yi Zuo, a professor of developmental biology at UCSC.
One caveat up front. Everything here was proven in mice, not people.
How did the researchers watch the brain change?
The team used two-photon microscopy, an advanced imaging technique that let them track individual neural structures in living mice over several weeks.
Their target was dendritic spines — tiny protrusions on neurons that receive signals from neighboring nerve cells. These spines help form synapses, the junctions through which neurons communicate. Synapses underpin learning, memory and emotional regulation.
Within 24 hours of a psilocybin dose, the mice showed a substantial increase in newly formed dendritic spines. The drug also accelerated how quickly those spines matured.
Normally, new spines start small and immature. Many vanish before becoming stable connections. After psilocybin, a much larger share grew into mushroom-shaped structures, the form linked to greater stability and stronger communication between neurons.
"These newly formed connections can integrate into existing neural circuitry and persist over time, leaving a lasting structural trace of psilocybin's effects on the brain," said Jacob Baker, first author of the study and a PhD student at UCSC.
The drug wasn't just adding connections, though. It was reorganizing existing ones too.
What happened in stressed mice?
The most intriguing results came from animals exposed to chronic, unpredictable mild stress, a condition known to disrupt neural circuitry and drive the loss of synaptic connections.
Psilocybin's effect depended on the brain's starting condition. In stressed mice, the drug produced an especially strong increase in new spine formation while also cutting the excessive loss of existing connections. In mice without chronic stress, the initial burst of new spines gradually subsided over three weeks, and some pre-existing connections were eliminated — a pattern of remodeling rather than simple growth.
"These findings challenge the prevailing view that psilocybin simply increases neural connectivity and suggest that its effects depend on the brain's underlying condition," Zuo said.
The results raise the possibility that psilocybin could help restore neural circuits disrupted by stress. But the study did not establish that these structural changes translate into improvements in depression or other psychiatric conditions.
In short: same drug, different wiring outcomes depending on stress history.
How did they separate rewiring from the trip?
This is where the study breaks new ground. The researchers asked whether the structural changes could be pulled apart from the effects that make psilocybin a psychedelic at all.
They focused on serotonin 2A receptors, or 5-HT2ARs — proteins on cell surfaces that respond to chemical signals and sit at the center of how classic psychedelics work. Specifically, they looked at Layer 5 pyramidal neurons, a population of cells in the cerebral cortex that sends information to other brain regions and carries high levels of these receptors.
Using genetically modified mice, the team ran two experiments:
- First, they restored the receptors exclusively in Layer 5 pyramidal neurons. Psilocybin still stimulated new synapse formation and maturation, but the mice showed no head-twitch response — a repetitive movement researchers use as a rodent stand-in for psychedelic activity.
- Then they flipped it, removing the receptors from those same neurons. This time psilocybin could no longer produce the structural changes, yet the head-twitch response persisted.
The contrast was striking. Serotonin 2A receptors on these particular neurons were necessary for psilocybin to remodel neural connections, but not for the head twitch. Restoring them only there was enough to recover the structural changes without the twitch.
The two effects, in other words, can be separated simply by changing where the receptor shows up in the brain.
There's a limit to what the behavior means. The head twitch doesn't directly establish whether mice experience hallucinations. What the experiments show is that the cellular mechanism behind structural brain change can operate independently of this particular psychedelic-associated response.
The takeaway: rewiring and tripping appear to ride on different cellular pathways.
Could this lead to non-hallucinogenic medicines?
The findings matter for drug development. They point toward treatments that boost neuroplasticity — the brain's ability to adapt by forming new connections between nerve cells and reorganizing old ones. That ability is critical because conditions like depression and post-traumatic stress disorder disrupt the brain circuits involved in mood and behavior.
If researchers can design compounds that trigger this rebuilding without psychedelic effects, patients could get some of psilocybin's benefits without the intense experience. Such drugs could also be easier to administer, without the level of supervision that psychedelic-assisted therapy currently demands.
"By showing that therapeutic circuit remodeling and hallucinogenic effects operate through distinct cellular pathways, our study provides a promising blueprint for designing non-hallucinogenic drug analogs," Zuo said.
What are the study's limits?
The gap between mice and medicine is wide. The researchers measured structural changes in neural connections, not clinical improvements in mental health. They also haven't shown that any drug can reliably reproduce these changes in humans without causing psychedelic effects.
For now, the biggest finding isn't that scientists have eliminated the trip. It's that they've identified a cellular mechanism that could one day make that possible while preserving some of psilocybin's effects on the brain.
The blueprint exists. Turning it into a pill is the next, much harder, step.
via zmescience.com (Source)
More from Elena Vasquez
Show full bio
Correspondent covering money, funding and market shifts around general science news at SciBeat.
458 articles
Nearby plates
- Single Magic Mushroom Dose Can Anatomically Change the Brain
- Five Labs, One Psychedelic: Psilocybin's Lasting Effects Fail Replication
- McGill Launches Largest-Ever Psychedelics Study for Mental Health
- Florida mushroom contains both psilocybin and toxic amatoxins
- Short-Acting Psychedelic Tested Against Major Depression in Phase IIa Trial